Manufacturer record
Oscar Remedies Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
18 batches manufactured by Oscar Remedies Pvt. Ltd (Haryana) were declared Not of Standard Quality between March 2019 and August 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: V250519, Dexamethasone Sodium Phosphate Injection IP (exp Apr 2027). DTL, Jaipur (state lab) found it not of standard quality: The sample does not conforms to the IP with respect to Sterility and Free Dexamethasone. Listed in the August 2026 alert.
Records by type
18 records linked to Oscar Remedies Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate Injection IP | Batch V250519Mfg May 2025 · Exp Apr 2027 | The sample does not conforms to the IP with respect to Sterility and Free Dexamethasone.Sterility | DTL, JaipurState lab | Aug 2026 |
| DEC-Plus | Batch T2604049Mfg Apr 2026 · Exp Mar 2028 | The content of Etoricoxib found to be 51.94 mg per tablet against labelled claim of 60 mg per tablet.Labelling | SDTL, PunjabState lab | Aug 2026 |
| Dexamethasone Sodium Phosphate Injection IP 10 ml | Batch V250909Mfg Sep 2025 · Exp Aug 2027 | The sample does not conform to the IP with respect to Assay of Dexamethasone Sodium Phosphate eq. to Dexamethasone Phosphate.Assay | DTL JaipurState lab | May 2026 |
| Amikacin Sulphate Injection I.P. | Batch V251007CMfg Oct 2025 · Exp Sep 2027 | The sample does not conform to I.P. with respect to test for Particulate matter and Description.Description | CDL, KolkataCDSCO lab | Mar 2026 |
| Fluorometholone Ophthalmic Solution USP | Batch E240423AMfg Apr 2024 · Exp Mar 2026 | Test for SterilitySterility | DTL, Bengaluru, KarnatakaState lab | Nov 2025 |
| Amikacin Sulphate Injection IP (Amised 100) | Batch V250114AMfg Jan 2025 · Exp Dec 2026 | Test for SterilitySterility | DTL, Bengaluru, KarnatakaState lab | Oct 2025 |
| Osocip-D Eye/Ear drops Ciprofloxacin & Dexamethasone Eye/Ear drops IP | Batch E240113AMfg Jan 2024 · Exp Dec 2025 | Content of Ciprofloxacin in the sample is more (i.e 943.33% of the labelled amount) than the permissible limits. 2. identification test for the presence of Dexamethasone Sodium Phosphate. 3. The sample gives high performance liquid chromatographic identification test for the presence of Dexamethasone. 4. The content of Dexamthasone in the sample is 0.078% W/V. 5. Name of the sample: Ciprofloxacin & Dexamethasone Eye/Ear drops IP 2022.Identification | FDA Lab , MumbaiCDSCO lab | Jun 2025 |
| Oscorcip-D Eye/Ear Drops | Batch E24020AMfg Feb 2024 · Exp Jan 2026 | 1. The content of Ciprofloxacin in the sample is more (i.e 1023.33% of the labelled amount) than the permissible limits. 2. The sample does not give HPLC identification test for the presence of Dexamethasone sodium phosphate. 3. The sample gives HPLC identification test for the presence of Dexamethasone. 4. The content of Dexamethasone in the sample is 0.066% w/v 5. Test for the sterility.Identification | FDA Lab , MumbaiCDSCO lab | Jun 2025 |
| Calamine Lotion IP | Batch 2451Mfg Jul 2024 · Exp Jun 2026 | Content of zinc oxideOther | CDTL ChennaiCDSCO lab | Jun 2025 |
| Spironolacto ne Tablets IP | Batch T- 2403993Mfg Mar 2024 · Exp Feb 2026 | Sample does not conform to IP specification for Spironolactone Tablets with respect to DissolutionDissolution | DTL ChennaiState lab | Jan 2025 |
| Clopidogrel Tablets IP (Clopirel-75) | Batch T-2401753Mfg Jan 2024 · Exp Dec 2025 | DissolutionDissolution | CDL KolkataCDSCO lab | Nov 2024 |
| Meropenem Injection IP (ZENEM 1 g INJECTION) | Batch B240720DMfg Jul 2024 · Exp Jun 2026 | Particulate matter and Content of SodiumParticulate matter | RDTL ChandigarhCDSCO lab | Oct 2024 |
| Fexofenadine Hydrochloride Tablets I.P. | Batch T-2403971Mfg Mar 2023 · Exp Feb 2026 | Dissolution of Fexofenadine Hydrochloride.Dissolution | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Fexofenadine Hydrochloride Tablets IP | Batch T-2403971Mfg Mar 2024 · Exp Feb 2026 | Uniformity of Weight and DissolutionDissolution | RDTL GuwahatiCDSCO lab | Sep 2024 |
| Ovit Cee Tablets (Ascorbic Acid Tablets IP) | Batch T-2306-08Mfg Jun 2023 · Exp Nov 2024 | Assay of 'Ascorbic Acid' and DescriptionAssay | CDL KolkataCDSCO lab | Dec 2023 |
| MEROXIA Nano Injection 1 gm (Meropenem Injection I.P.) | Batch D220162Mfg Jan 2022 · Exp Dec 2023 | Assay of Meropenem & Content of SodiumAssay | CDL KolkataCDSCO lab | Mar 2023 |
| Prednisolone Acetate and Moxifloxacin Ophthalmic Suspension(M- Floxin-P Eye Drops) | Batch O-066Mfg Apr 2018 · Exp Mar 2020 | Particle size and Assay of Predisolone AcetateAssay | RDTL ChandigarhState lab | Jul 2019 |
| CEFUROXIME AXETIL TABLETS I.P. (AXTUM-500) | Batch BT-1804-06Mfg Apr 2018 · Exp Mar 2020 | DissolutionDissolution | RDTL GuwahatiState lab | Mar 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.